could-the-market-be-wrong-about-vertex-pharmaceuticals-incorporated-(nasdaq:vrtx)-given-its-attractive-financial-prospects?

Could The Market Be Wrong About Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given Its Attractive Financial Prospects?

View photos

Vertex Pharmaceuticals’ ROE in this article.” data-reactid=”28″ type=”text”>It is hard to get excited after looking at Vertex Pharmaceuticals’ (NASDAQ:VRTX) recent performance, when its stock has declined 5.0% over the past three months. But if you pay close attention, you might gather that its strong financials could mean that the stock could potentially see an increase in value in the long-term, given how markets usually reward companies with good financial health. Specifically, we decided to study Vertex Pharmaceuticals’ ROE in this article.

Return on equity or ROE is a key measure used to assess how efficiently a company’s management is utilizing the company’s capital. Put another way, it reveals the company’s success at turning shareholder investments into profits.

See our latest analysis for Vertex Pharmaceuticals ” data-reactid=”30″ type=”text”> See our latest analysis for Vertex Pharmaceuticals

How Do You Calculate Return On Equity?

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders’ Equity

So, based on the above formula, the ROE for Vertex Pharmaceuticals is:

28% = US$2.1b ÷ US$7.5b (Based on the trailing twelve months to June 2020).

The ‘return’ is the yearly profit. One way to conceptualize this is that for each $1 of shareholders’ capital it has, the company made $0.28 in profit.

What Has ROE Got To Do With Earnings Growth?

Thus far, we have learned that ROE measures how efficiently a company is generating its profits. We now need to evaluate how much profit the company reinvests or “retains” for future growth which then gives us an idea about the growth potential of the company. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don’t share these attributes.

A Side By Side comparison of Vertex Pharmaceuticals’ Earnings Growth And 28% ROE

To begin with, Vertex Pharmaceuticals has a pretty high ROE which is interesting. Additionally, the company’s ROE is higher compared to the industry average of 14% which is quite remarkable. Under the circumstances, Vertex Pharmaceuticals’ considerable five year net income growth of 69% was to be expected.

We then compared Vertex Pharmaceuticals’ net income growth with the industry and we’re pleased to see that the company’s growth figure is higher when compared with the industry which has a growth rate of 27% in the same period.

past-earnings-growth

infographic on the company’s intrinsic value has everything you need to know.” data-reactid=”58″ type=”text”>Earnings growth is a huge factor in stock valuation. It’s important for an investor to know whether the market has priced in the company’s expected earnings growth (or decline). This then helps them determine if the stock is placed for a bright or bleak future. Is VRTX fairly valued? This infographic on the company’s intrinsic value has everything you need to know.

Is Vertex Pharmaceuticals Using Its Retained Earnings Effectively?

Given that Vertex Pharmaceuticals doesn’t pay any dividend to its shareholders, we infer that the company has been reinvesting all of its profits to grow its business.

Conclusion

report on analyst forecasts for the company to find out more.” data-reactid=”62″ type=”text”>Overall, we are quite pleased with Vertex Pharmaceuticals’ performance. In particular, it’s great to see that the company is investing heavily into its business and along with a high rate of return, that has resulted in a sizeable growth in its earnings. With that said, the latest industry analyst forecasts reveal that the company’s earnings growth is expected to slow down. To know more about the company’s future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.

Get in touch with us directly. Alternatively, email [email protected].” data-reactid=”67″ type=”text”>

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected].

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top